Roche’s Tecentriq/chemo combo smashes both co-primary endpoints at Phase 3
pharmafile | May 29, 2018 | News story | Manufacturing and Production, Research and Development | Cancer, NSCLC, Roche, immunotherapy, lung cancer, pharma, tecentriq
Roche has lifted the curtain on new Phase 3 data for its anti-PD-L1 cancer immunotherapy Tecentriq (atezolizumab), showing that the drug met its co-primary endpoints when used in combination with carboplatin and Abraxane chemotherapy in the first-line treatment of metastatic non-squamous non-small cell lung cancer (NCSLC).
The Phase 3 results showed that the Tecentriq/chemotherapy combo “significantly” improved overall survival and reduced the risk of disease progression or death compared to chemotherapy alone. The therapy’s safety profile was also found to be consistent with previous data. A full report of the findings will be announced at an upcoming oncology congress.
“The results of the IMpower130 study add to the growing evidence showing the clinical benefit of Tecentriq-based combinations in the treatment of advanced non-squamous non-small cell lung cancer,” commented Dr Sandra Horning, Roche’s Chief Medical Officer and Head of Global Product Development. “We will share these results with global health authorities with the goal of bringing this potential treatment option to people with this disease.”
The new findings mark the third positive study of Tecentriq’s effectiveness alone or as a combination in the treatment of NSCLC, another key step in its pursuit of MSD’s Keytruda and BMS’ Opdivo. Roche currently has eight trials underway for the drug in the lung cancer space.
Matt Fellows
Related Content
Roche’s Alecensa approved by FDA as lung cancer treatment
Roche has announced that the US Food and Drug Administration (FDA) has approved Alecensa (alectinib) …
Genentech’s Columbi meets primary endpoint in phase 3 trial for lymphoma treatment
Genentech, part of the Roche Group, has announced that its phase 3 STARGLO trial has …
FDA clears Oryzon’s phase 1/2 trial for lung cancer treatment
Oryzon Genomics has announced that the US Food and Drug Administration (FDA) has approved its …